ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Wyeth inks protein deal with Ablynx ...

November 13, 2006 | APPEARED IN VOLUME 84, ISSUE 46

Wyeth Pharmaceuticals and Ablynx have agreed to discover, develop, and commercialize Ablynx's therapeutic proteins, trade-named Nanobodies, which are directed at the tumor necrosis factor alpha protein and its receptors. Ablynx will receive an initial payment, research support, and milestone payments that could total $212.5 million. In addition, Ablynx will receive royalties on product sales.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment